Overview

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

Status:
Unknown status

Trial end date:
2020-12-16

Target enrollment:

Participant gender:

Summary

It is postulated that focal sensitizing radiotherapy may potentiate the effectiveness of durvalumab. The purpose of this study is to test the safety and tolerability of 2 different dose levels of focal sensitizing radiation therapy given with durvalumab.

Phase:

Phase 1

Details

Lead Sponsor:

British Columbia Cancer Agency

Collaborator:

Ozmosis Research Inc.

Treatments:

Antibodies, Monoclonal
Durvalumab